Ownership and insider activity for Inotiv, Inc. (NOTV): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. The company operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS).
Price
| Price | $0.08 |
| Market Cap | $3M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-18 | Taylor Beth A. | F-InKind | 5,864 | $108 |
| 2026-06-18 | Sagartz John E | F-InKind | 6,071 | $112 |
| 2026-06-18 | Hardy Adrian | F-InKind | 5,371 | $99 |
| 2026-06-18 | Freeman Jeffrey Brennan | F-InKind | 5,855 | $108 |
| 2026-06-18 | Castetter Andrea | F-InKind | 5,800 | $107 |
| 2026-06-18 | Beattie John Gregory | F-InKind | 5,769 | $107 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $386000 | $434000 | $773000 | $606000 | $1.4M | $138.9M | $18.5M | $35.5M | $21.4M | $21.7M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $2.2M | $3.1M | $5.1M | $9.5M | $10.8M | $28.4M | $100.1M | $90.4M | $77.4M | $97.4M |
| Inventory | $1.5M | $913000 | $1.2M | $1.1M | $700000 | $602000 | $71.4M | $56.1M | $18.2M | $45.7M |
| Total Current Assets | $4.9M | $5.3M | $8.1M | $12.4M | $15.3M | $189.0M | $233.0M | $213.8M | $163.4M | $194.6M |
| Property, Plant & Equipment | $16.1M | $15.0M | $16.6M | $22.8M | $37.5M | $56.4M | $218.7M | $229.9M | $237.5M | $227.1M |
| Goodwill | $38000 | $38000 | $3.1M | $3.6M | $4.4M | $51.9M | $157.8M | $94.3M | $94.3M | $94.3M |
| Intangible Assets | 0 | 0 | $3.3M | $2.9M | $4.3M | $24.2M | $345.9M | $308.4M | $274.4M | $240.2M |
| Total Assets | $21.1M | $20.4M | $31.3M | $42.0M | $61.6M | $321.9M | $962.9M | $856.5M | $781.4M | $771.1M |
| Accounts Payable | $3.0M | $2.1M | $3.2M | $4.9M | $3.2M | $6.2M | $28.7M | $32.6M | $33.5M | $48.5M |
| Short-term Debt | $5.0M | $352000 | $996000 | $2.2M | $6.9M | $11.4M | $23.0M | $8.0M | $3.5M | $405.1M |
| Total Current Liabilities | $13.5M | $7.7M | $11.8M | $17.5M | $31.6M | $55.1M | $164.1M | $132.2M | $119.0M | $556.8M |
| Long-term Debt | 0 | $4.2M | $8.5M | $13.8M | $18.8M | $154.2M | $330.7M | $369.8M | $389.8M | $44.3M |
| Total Liabilities | $13.7M | $11.9M | $20.4M | $31.3M | $54.0M | $216.7M | $603.1M | $588.0M | $610.9M | $635.1M |
| Retained Earnings | -$16.9M | -$16.0M | -$16.2M | -$17.1M | -$21.9M | -$11.0M | -$348.3M | -$453.3M | -$562.2M | -$630.8M |
| Total Equity | $7.5M | $8.5M | $10.9M | $10.7M | $7.6M | $105.1M | $360.4M | $269.2M | $170.5M | $136.0M |
| Total Debt | $5.3M | $4.7M | $9.7M | $16.6M | $36.4M | $174.2M | $386.5M | $417.6M | $445.1M | $503.6M |
| Net Debt | $5.0M | $4.3M | $8.9M | $16.0M | $35.0M | $35.3M | $368.0M | $382.1M | $423.7M | $481.9M |
| Working Capital | -$8.6M | -$2.4M | -$3.7M | -$5.1M | -$16.3M | $133.9M | $68.9M | $81.6M | $44.4M | -$362.2M |
Financial Health
| Debt / Equity | 6.33 |
| Current Ratio | 0.27 |
Profitability
| Return on Equity | -74.67% |
| Return on Invested Capital | -6.25% |
| Return on Assets | -12.38% |
| Gross Margin | 14.70% |
| Operating Margin | -8.87% |
| Net Margin | -17.14% |
Related companies: BDSX · BEAT · BIAF · CELU · FGEN · KZR · QNTM
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of NOTV: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks